Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

• Published in: Molecular neurodegeneration Vol. 18; no. 1; pp. 18 - 12
• Main Authors: Gonzalez-Ortiz, Fernando, Kac, Przemysław R., Brum, Wagner S., Zetterberg, Henrik, Blennow, Kaj, Karikari, Thomas K.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.03.2023; BioMed Central; BMC
• Subjects: Advertising executives; Alzheimer; Alzheimer Disease - diagnosis; Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Autopsy; Biomarkers; Biomarkers - cerebrospinal fluid; Blood biomarker; Cerebrospinal fluid; Clinical trials; Cognitive ability; Cognitive Dysfunction; Dementia; Dementia disorders; Diagnosis; Diagnostic imaging; Humans; Neurodegeneration; Neurodegenerative diseases; Neuroimaging; Neuropathology; Neurosciences; Neurovetenskaper; Pathology; Phosphorylated tau; Plasma p-tau; Review; s disease; Standardization; Tau protein; tau Proteins - cerebrospinal fluid; Phosphorylated tau; s disease; Plasma p-tau; Alzheimer; Blood biomarker; Dementia
• ISSN: 1750-1326; 1750-1326
• DOI: 10.1186/s13024-023-00605-8

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence and clinical symptoms, challenges regarding practicality and accessibility hinder their widespread availability and implementation. Consequently, many people with suspected cognitive impairment due to AD do not receive a biomarker-supported diagnosis. Blood biomarkers have the capacity to help expand access to AD diagnostics worldwide. One such promising biomarker is plasma phosphorylated tau (p-tau), which has demonstrated specificity to AD versus non-AD neurodegenerative diseases, and will be extremely important to inform on clinical diagnosis and eligibility for therapies that have recently been approved. This review provides an update on the diagnostic and prognostic performances of plasma p-tau181, p-tau217 and p-tau231, and their associations with in vivo and autopsy-verified diagnosis and pathological hallmarks. Additionally, we discuss potential applications and unanswered questions of plasma p-tau for therapeutic trials, given their recent addition to the biomarker toolbox for participant screening, recruitment and during-trial monitoring. Outstanding questions include assay standardization, threshold generation and biomarker verification in diverse cohorts reflective of the wider community attending memory clinics and included in clinical trials.